Fujifilm Biotechnologies Unveils £400m Expansion in Billingham
Fujifilm Biotechnologies has officially unveiled its £400 million expansion of the biopharmaceutical facility in Billingham. This site is now the largest single-use contract development and manufacturing organization (CDMO) in the UK. The expansion enhances Fujifilm’s ability to manufacture advanced medicines, vaccines, and biologics.
Key Features of the Expanded Facility
Following the investment, the Billingham site has increased its total area to 1.6 million square feet. This includes:
- A new bioreactor capacity of 19,000 liters.
- A Bioprocess Innovation Centre with over 102,200 square feet of laboratory space.
- Increased employment, with 960 people currently working at the site.
Operational Timeline
The new factory is scheduled to become operational in the first half of 2026. This expansion aligns with Fujifilm’s strategic goal of enhancing its global manufacturing capabilities.
Impact on Healthcare and the Economy
The expansion is expected to bolster the UK’s position in biomanufacturing. Fujifilm aims to enhance its ability to produce complex medicines for various conditions, including:
- Cancer.
- Neurodegenerative diseases.
- Rare disorders.
Chancellor Rachel Reeves emphasized that this investment reflects the UK’s strong appeal as a leader in developing innovative medicines, which is crucial for job creation and the local economy.
Global Network Integration
The Billingham facility will work closely with Fujifilm’s biomanufacturing site in Toyama, Japan. This integration is part of Fujifilm’s kojoX network, designed to improve the scalability and efficiency of medicine production.
Toshihisa Iida, chairman of Fujifilm Biotechnologies, noted that this expansion represents a commitment to meet rising global demands for innovative pharmaceutical solutions. The facility will support partners in developing therapies from initial stages through to early clinical manufacturing.
Conclusion
Fujifilm Biotechnologies is poised to transform the biopharmaceutical landscape in the UK with its significant investment in Billingham. This expansion not only enhances production capabilities but also reinforces the region’s reputation as a hub of innovation in life sciences.
